MLEC
Moolec Science S.A.
Biotechnology
Market Cap$7M
5Y Perf.-7.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MLEC vs SLP
Revenue, margins, valuation, and 5-year total return — side by side.
SLP
Simulations Plus, Inc.
Medical - Healthcare Information Services
Market Cap$324M
5Y Perf.-74.6%
MLEC vs SLP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MLEC | SLP |
|---|---|---|
| Industry | Biotechnology | Medical - Healthcare Information Services |
| Market Cap | $7M | $324M |
| Revenue (TTM) | $8M | $79M |
| Net Income (TTM) | $-8M | $-64M |
| Gross Margin | -8.2% | 59.6% |
| Operating Margin | -116.7% | -89.2% |
| Forward P/E | — | 18.0x |
| Total Debt | $247M | $616K |
| Cash & Equiv. | $768K | $31M |
MLEC vs SLP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MLEC
SLP
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Moolec Science S.A. (MLEC) | 100 | 92.6 | -7.4% |
| Simulations Plus, I… (SLP) | 100 | 25.4 | -74.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MLEC vs SLP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MLEC leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Simulations Plus, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
MLEC
Moolec Science S.A.
The Income Pick
MLEC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.89
- Rev growth 58.3%, EPS growth -89.8%
- Lower volatility, beta 0.89, current ratio 0.13x
Best for: income & stability and growth exposure
SLP
Simulations Plus, Inc.
The Long-Run Compounder
SLP is the clearest fit if your priority is long-term compounding.
- 104.0% 10Y total return vs MLEC's -8.5%
- -81.7% margin vs MLEC's -105.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MLEC | 58.3% revenue growth vs SLP's 13.1% |
| Quality / Margins | SLP | -81.7% margin vs MLEC's -105.7% |
| Stability / Safety | MLEC | Beta 0.89 vs SLP's 1.25 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MLEC | -2.0% vs SLP's -44.6% |
| Efficiency (ROA) | MLEC | -26.6% ROA vs SLP's -46.6%, ROIC -8.8% vs -39.6% |
MLEC vs SLP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
MLEC vs SLP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSLPLAGGINGMLEC
MLECMoolec Science S.A.
0leads
SLPSimulations Plus, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs MLECMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SLP5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SLP4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SLP leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SLP is the larger business by revenue, generating $79M annually — 10.0x MLEC's $8M. SLP is the more profitable business, keeping -81.7% of every revenue dollar as net income compared to MLEC's -105.7%. On growth, MLEC holds the edge at +9.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MLECMoolec Science S.… | SLPSimulations Plus,… |
|---|---|---|
| RevenueTrailing 12 months | $8M | $79M |
| EBITDAEarnings before interest/tax | -$8M | -$63M |
| Net IncomeAfter-tax profit | -$8M | -$64M |
| Free Cash FlowCash after capex | -$6M | $23M |
| Gross MarginGross profit ÷ Revenue | -8.2% | +59.6% |
| Operating MarginEBIT ÷ Revenue | -116.7% | -89.2% |
| Net MarginNet income ÷ Revenue | -105.7% | -81.7% |
| FCF MarginFCF ÷ Revenue | -78.1% | +29.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.5% | -2.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.0% | +2.3% |
SLP leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — MLEC and SLP each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MLECMoolec Science S.… | SLPSimulations Plus,… |
|---|---|---|
| Market CapShares × price | $7M | $324M |
| Enterprise ValueMkt cap + debt − cash | $253M | $293M |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -4.99x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 18.01x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 21.45x | — |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 4.09x |
| Price / BookPrice ÷ Book value/share | — | 2.59x |
| Price / FCFMarket cap ÷ FCF | — | 18.58x |
Evenly matched — MLEC and SLP each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
SLP leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
SLP delivers a -50.5% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-151 for MLEC. On the Piotroski fundamental quality scale (0–9), SLP scores 6/9 vs MLEC's 4/9, reflecting solid financial health.
| Metric | MLECMoolec Science S.… | SLPSimulations Plus,… |
|---|---|---|
| ROE (TTM)Return on equity | -150.9% | -50.5% |
| ROA (TTM)Return on assets | -26.6% | -46.6% |
| ROICReturn on invested capital | -8.8% | -39.6% |
| ROCEReturn on capital employed | — | -44.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | $246M | -$30M |
| Cash & Equiv.Liquid assets | $767,919 | $31M |
| Total DebtShort + long-term debt | $247M | $616,000 |
| Interest CoverageEBIT ÷ Interest expense | -2.94x | — |
SLP leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — MLEC and SLP each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MLEC five years ago would be worth $9,201 today (with dividends reinvested), compared to $2,950 for SLP. Over the past 12 months, MLEC leads with a -2.0% total return vs SLP's -44.6%. The 3-year compound annual growth rate (CAGR) favors SLP at -26.0% vs MLEC's -33.1% — a key indicator of consistent wealth creation.
| Metric | MLECMoolec Science S.… | SLPSimulations Plus,… |
|---|---|---|
| YTD ReturnYear-to-date | +3153.6% | -11.3% |
| 1-Year ReturnPast 12 months | -2.0% | -44.6% |
| 3-Year ReturnCumulative with dividends | -70.1% | -59.6% |
| 5-Year ReturnCumulative with dividends | -8.0% | -70.5% |
| 10-Year ReturnCumulative with dividends | -8.5% | +104.0% |
| CAGR (3Y)Annualised 3-year return | -33.1% | -26.0% |
Evenly matched — MLEC and SLP each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MLEC and SLP each lead in 1 of 2 comparable metrics.
Risk & Volatility
MLEC is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than SLP's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SLP currently trades 47.2% from its 52-week high vs MLEC's 38.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MLECMoolec Science S.… | SLPSimulations Plus,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.89x | 1.25x |
| 52-Week HighHighest price in past year | $23.22 | $34.01 |
| 52-Week LowLowest price in past year | $0.20 | $11.09 |
| % of 52W HighCurrent price vs 52-week peak | +38.7% | +47.2% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 67.9 |
| Avg Volume (50D)Average daily shares traded | 319K | 315K |
Evenly matched — MLEC and SLP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MLECMoolec Science S.… | SLPSimulations Plus,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $56.00 |
| # AnalystsCovering analysts | — | 8 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 4 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +14.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SLP leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
Best OverallSimulations Plus, Inc. (SLP)Leads 2 of 6 categories
Loading custom metrics...
MLEC vs SLP: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MLEC or SLP a better buy right now?
For growth investors, Moolec Science S.
A. (MLEC) is the stronger pick with 58. 3% revenue growth year-over-year, versus 13. 1% for Simulations Plus, Inc. (SLP). Analysts rate Simulations Plus, Inc. (SLP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MLEC or SLP?
Over the past 5 years, Moolec Science S.
A. (MLEC) delivered a total return of -8. 0%, compared to -70. 5% for Simulations Plus, Inc. (SLP). Over 10 years, the gap is even starker: SLP returned +104. 0% versus MLEC's -8. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MLEC or SLP?
By beta (market sensitivity over 5 years), Moolec Science S.
A. (MLEC) is the lower-risk stock at 0. 89β versus Simulations Plus, Inc. 's 1. 25β — meaning SLP is approximately 41% more volatile than MLEC relative to the S&P 500.
04Which is growing faster — MLEC or SLP?
By revenue growth (latest reported year), Moolec Science S.
A. (MLEC) is pulling ahead at 58. 3% versus 13. 1% for Simulations Plus, Inc. (SLP). On earnings-per-share growth, the picture is similar: Simulations Plus, Inc. grew EPS -757. 1% year-over-year, compared to -89. 8% for Moolec Science S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MLEC or SLP?
Moolec Science S.
A. (MLEC) is the more profitable company, earning -33. 4% net margin versus -81. 7% for Simulations Plus, Inc. — meaning it keeps -33. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLEC leads at -3. 1% versus -89. 3% for SLP. At the gross margin level — before operating expenses — SLP leads at 58. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MLEC or SLP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MLEC or SLP better for a retirement portfolio?
For long-horizon retirement investors, Moolec Science S.
A. (MLEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89)). Both have compounded well over 10 years (MLEC: -8. 5%, SLP: +104. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MLEC and SLP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MLEC is a small-cap high-growth stock; SLP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(MLEC: 948.3% · SLP: -2.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.